GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — have become the most-prescribed weight-loss drugs in the country, and a lot of the men taking them are also asking a quieter question: what is this doing to my testosterone and my erectile function? The honest answer isn't the clean win that some weight-loss marketing implies. The testosterone evidence is genuinely encouraging. The erectile function evidence is more mixed than most summaries let on, including one large real-world study that found the opposite of what you'd expect [2].
Track This Biomarker — Free
Don't let a number on a lab report disappear into a drawer. Log it in ManCore's biomarker tracker and watch how it trends over months as you adjust training, diet, and sleep.
What GLP-1 Drugs Actually Do
GLP-1 receptor agonists mimic a gut hormone (glucagon-like peptide-1) that signals fullness to the brain and slows gastric emptying, which is why they produce substantial, sustained appetite reduction and weight loss — commonly 10-20% of body weight over roughly a year in clinical trials. They were originally developed for type 2 diabetes and later approved specifically for weight management. That weight loss is the main lever behind most of what these drugs do to male hormones — this is a story about fat loss changing hormone physiology, more than about the drug acting directly on the testes.
The Testosterone Evidence: A Real, Measurable Increase
A 2025 systematic review and meta-analysis pooling seven studies (680 men) found GLP-1 receptor agonist treatment produced a significant increase in total testosterone, along with increases in free testosterone, sex hormone-binding globulin (SHBG), LH, and FSH — while weight, BMI, and waist circumference decreased [1]. The size of the testosterone increase correlated with how much weight and BMI a man actually lost, which points squarely at the underlying mechanism: excess body fat, particularly visceral fat, runs high aromatase activity that converts testosterone into estrogen, and it also blunts the hypothalamic-pituitary-gonadal (HPG) signaling that tells the testes to produce testosterone in the first place. Lose the fat, and both of those pressures ease up.
- •The testosterone benefit is well-documented specifically in men with obesity-related low testosterone (functional hypogonadism) — it is not a general testosterone booster for men who are already lean
- •Effect size tracked with weight/BMI change in the meta-regression — more weight lost, more testosterone gained, reinforcing that this runs through fat loss rather than a direct testicular effect [1]
- •The authors were explicit that current evidence does not demonstrate a direct action of GLP-1 drugs on testicular function itself — the improvement is best explained as downstream of weight loss
The Erectile Function Picture Is More Complicated
This is where the evidence stops being a tidy story. A 2023 retrospective cohort study of 108 men with type 2 diabetes and existing erectile dysfunction found that adding a GLP-1 drug to metformin improved IIEF5 erectile function scores significantly more than metformin alone over 12 months, alongside better glucose control and the testosterone increase described above [3]. That's the result that tends to get quoted.
But a 2024 database study using the TriNetX research network looked at a different population — non-diabetic, obese men aged 18-50 with no prior ED diagnosis — and found the opposite direction of effect: men prescribed semaglutide for weight loss were significantly more likely to receive a new erectile dysfunction diagnosis and/or a PDE5-inhibitor prescription than matched men who were never prescribed it (1.47% vs 0.32%, a 4.5-fold relative risk), and were also more likely to be newly diagnosed with testosterone deficiency (1.9-fold relative risk) [2]. A separate 2024 randomized trial comparing semaglutide against testosterone replacement therapy in men with diabetes and functional hypogonadism found both treatments raised testosterone similarly, but only the TRT group showed a statistically significant improvement in IIEF-15 erectile function scores — semaglutide's improvement did not reach significance in that comparison [4].
The likeliest explanation for the mismatch is population and detection differences rather than a true contradiction: the study finding increased ED risk looked at non-diabetic men with no prior diagnosis, where starting a new prescription and seeing a doctor more often can itself surface a pre-existing issue that was never formally diagnosed before — a form of detection bias the authors themselves note as a limitation. The studies finding improvement enrolled men who already had diagnosed diabetes and existing ED, a population where glucose control and weight loss have a more direct, established therapeutic pathway to better erectile function. Track your own symptoms rather than assuming either direction applies to you — that's exactly what the [ManCore dashboard](/dashboard) is built for.
Sperm Quality: A Data Point Worth Knowing
The 2024 randomized trial comparing semaglutide to TRT also measured semen quality, which matters for men weighing the two options who still want to have children. Semaglutide significantly improved sperm morphology (the percentage of normally-shaped sperm) over 24 weeks, while sperm concentration and total count declined significantly in the TRT group — a known effect of testosterone therapy, which suppresses the body's own sperm-producing signaling [4]. For a man with obesity-related low testosterone who is also trying to conceive, that's a meaningful practical difference between the two approaches, independent of which one moves the testosterone number more.
What This Means If You're Starting a GLP-1 Drug
- •Expect testosterone changes to lag behind the weight loss itself — the meta-analysis mechanism runs through reduced aromatase activity and improved HPG signaling as fat comes off, not an immediate drug effect
- •Don't assume erectile function will automatically improve alongside testosterone — the evidence genuinely points in different directions depending on the population, so track your own symptoms rather than assuming either outcome
- •If new erectile difficulty shows up after starting a GLP-1 drug, mention it to your prescriber rather than dismissing it as unrelated — the real-world database signal is large enough (4.5x relative risk in that cohort) to be worth a conversation, not necessarily a reason to stop the medication [2]
- •Diabetes and general metabolic health remain relevant background factors — the studies showing the clearest erectile function benefit were in men with diabetes and pre-existing ED, a different starting point than a metabolically healthy man taking a GLP-1 drug purely for weight loss [3][5]
Related Reading
Does Losing Weight Increase Testosterone? How Body Fat Affects T Levels, Explained
The same weight-loss-to-testosterone mechanism underlying the GLP-1 research, explained on its own.
Testosterone Replacement Therapy: Forms, Dosing, and What to Realistically Expect
How TRT compares to GLP-1-driven weight loss as a path to raising testosterone, including the sperm-count tradeoff.
What Is Erectile Dysfunction? Causes, Symptoms & Complete Overview
Background on the vascular, hormonal, and neurological causes of ED referenced throughout this article.
Supplements for Hormonal Health Support
Male Optimization Formula
General testosterone-support formula worth discussing with your doctor alongside any GLP-1 treatment plan, not a substitute for it.
Snap Supplements Nitric Oxide Booster + Prostate Health
Supports healthy circulation, which plays a supporting role in vascular-driven erectile function independent of hormone levels.
Affiliate disclosure: ManCore earns a small commission on purchases made through these links at no extra cost to you.
Frequently Asked Questions
Does Ozempic raise testosterone?
In men with obesity-related low testosterone, yes — a 2025 meta-analysis of 680 men found significant increases in total and free testosterone with GLP-1 receptor agonist treatment, tracking with how much weight was lost. It is not established as a direct testicular effect independent of weight loss, and it is not a general testosterone booster for men who are not overweight [1].
Can semaglutide cause erectile dysfunction?
A large real-world database study found non-diabetic, obese men prescribed semaglutide for weight loss were 4.5 times more likely to receive a new ED diagnosis than matched men who weren't prescribed it. The authors note this could partly reflect increased healthcare contact surfacing pre-existing issues rather than the drug directly causing new dysfunction, but the signal is large enough to take seriously and discuss with a prescriber [2].
Do GLP-1 drugs help erectile dysfunction in men with diabetes?
In men with type 2 diabetes and existing ED, a 12-month cohort study found adding a GLP-1 drug to metformin improved erectile function scores significantly more than metformin alone. This is a different population than metabolically healthy men taking a GLP-1 drug purely for weight loss, where the evidence is less clearly favorable [3].
Is GLP-1-driven weight loss better than TRT for raising testosterone?
A randomized trial found both approaches raised testosterone similarly over 24 weeks. The meaningful difference was in sperm quality — semaglutide improved sperm morphology, while TRT significantly reduced sperm count and concentration, a well-known effect of testosterone therapy. For men still trying to conceive, that difference can matter more than the testosterone number itself [4].
How long does it take for testosterone to improve on a GLP-1 drug?
The research doesn't establish a fixed timeline, but since the effect runs through weight loss rather than a direct hormonal action, meaningful testosterone changes should be expected to track your weight-loss trajectory rather than show up immediately after starting the medication.
Should I stop a GLP-1 drug if I notice new erectile difficulty?
Don't stop or change a prescribed medication without talking to your prescriber first. New erectile difficulty after starting a GLP-1 drug is worth reporting and discussing, since it's a documented enough signal to warrant a conversation, but the same drug class also has evidence of improving erectile function in other populations — a prescriber can help sort out which factors apply to your specific situation.
The Bottom Line
GLP-1 drugs reliably raise testosterone in men with obesity-related low testosterone, driven by weight loss rather than a direct drug effect. Erectile function is the part worth going in with realistic expectations about — the evidence points in different directions depending on the population studied, and a real-world study found a meaningfully increased ED-diagnosis risk in non-diabetic men that deserves more attention than it usually gets in weight-loss drug coverage. Track your own numbers rather than assuming either outcome, and loop in your prescriber if something changes.